Supernus Pharmaceuticals Stock Forecast, Price & News

Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

Is Supernus Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Supernus Pharmaceuticals stock.
View analyst ratings for Supernus Pharmaceuticals or view top-rated stocks.

How has Supernus Pharmaceuticals' stock been impacted by Coronavirus?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SUPN stock has increased by 92.0% and is now trading at $31.00.
View which stocks have been most impacted by COVID-19.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Supernus Pharmaceuticals.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) posted its quarterly earnings data on Wednesday, November, 3rd. The specialty pharmaceutical company reported $0.40 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.19. The specialty pharmaceutical company had revenue of $148.46 million for the quarter, compared to the consensus estimate of $141.32 million. Supernus Pharmaceuticals had a net margin of 14.49% and a trailing twelve-month return on equity of 10.56%. During the same quarter in the prior year, the firm earned $0.74 EPS.
View Supernus Pharmaceuticals' earnings history.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided EPS guidance of for the period. The company issued revenue guidance of $550 million-$570 million, compared to the consensus revenue estimate of $560.68 million.

What price target have analysts set for SUPN?

2 brokers have issued 12-month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $35.00 to $44.00. On average, they expect Supernus Pharmaceuticals' share price to reach $39.50 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:

• Jack A. Khattar, President, CEO, Secretary & Director
• Timothy C. Dec, Chief Financial Officer & Senior Vice President
• Frank Mottola, Senior VP-Quality, GMP Operations & IT
• Padmanabh P. Bhatt, Chief Scientific Officer & Senior Vice President
• Jonathan Rubin, Chief Medical Officer & Senior Vice President

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals CEO Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among Supernus Pharmaceuticals' employees.

Who are some of Supernus Pharmaceuticals' key competitors?

Some companies that are related to Supernus Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Endo International (ENDP).
View all of SUPN's competitors.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (4.30%), Macquarie Group Ltd. (4.04%), Renaissance Technologies LLC (2.63%), Stephens Investment Management Group LLC (2.33%), Geode Capital Management LLC (1.80%) and Rice Hall James & Associates LLC (1.72%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends for Supernus Pharmaceuticals.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including Teton Advisors Inc., Frontier Capital Management Co. LLC, HealthInvest Partners AB, Foundry Partners LLC, LSV Asset Management, Renaissance Technologies LLC, Two Sigma Advisers LP, and Bridge City Capital LLC. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Stefan KF Schwabe, and Tami Tillotson Martin.
View insider buying and selling activity for Supernus Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was bought by a variety of institutional investors in the last quarter, including Epoch Investment Partners Inc., MESIROW FINANCIAL INVESTMENT MANAGEMENT Equity & Fixed Income, Victory Capital Management Inc., International Biotechnology Trust PLC, Voloridge Investment Management LLC, Mutual of America Capital Management LLC, Tudor Investment Corp Et Al, and Advisor Resource Council.
View insider buying and selling activity for Supernus Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $31.00.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals has a market capitalization of $1.64 billion and generates $520.40 million in revenue each year. The specialty pharmaceutical company earns $126.95 million in net income (profit) each year or $1.51 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

Supernus Pharmaceuticals employs 563 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

Where are Supernus Pharmaceuticals' headquarters?

Supernus Pharmaceuticals is headquartered at 1550 E GUDE DR, ROCKVILLE MD, 20850.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at [email protected], or via fax at 301-838-2501.